Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analyst: Diagnostics Sector R&D Spending Won't Match FDA Data Demands

This article was originally published in The Gray Sheet

Executive Summary

The R&D spend to revenue ratio at emerging and established pure-play diagnostic companies is not sufficient to meet growing FDA requirements for the space, a Morgan Stanley analyst argues.

You may also be interested in...



Abbott Follows Pfizer To FDA With Co-Developed Lung Cancer Diagnostic

A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.

FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time

The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Latest News
See All
UsernamePublicRestriction

Register

MT030276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel